Cutaneous T-cell lymphoma, new insights


Published: June 11, 2009
Abstract Views: 172
PDF: 155
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of extranodal non-Hodgkin lymphomas characterized by homing of the tumoral T-cells into the skin.1,2 The most frequent forms of CTCL are mycosis fungoides (MF) and its leukemic counterpart, the Sézary syndrome (SS). Currently, no curative treatment for CTCL is available, and the therapy aims to maintain a long-term complete remission and preserve quality of life. Patients with refractory or transformed MF and with SS have usually poor prognosis and the proposed treatment is mostly palliative.3

Supporting Agencies


Wozniak, M., Rodriguez Pinilla, S., Villuendas, R., Herrera, M., Ortiz, P., & Piris, M. (2009). Cutaneous T-cell lymphoma, new insights. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.539

Downloads

Citations